ValuentumAd

Official PayPal Seal

Cash-Rich Vertex Pharma Raises 2024 Product Revenue Guidance

publication date: Nov 6, 2024
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image: Vertex Pharma’s shares have done quite well the past couple years. 

We continue to like Vertex’s established position in cystic fibrosis and its opportunity in gene-editing therapies as well as a new class of medicine for acute pain (VX-548) that’s without the limitations of opioids. The company’s pipeline is also progressing nicely with three additional programs advancing to Phase 3 – suzetrigine in painful diabetic peripheral neuropathy (DPN), povetacicept in immunoglobulin A nephropathy (IgAN), and VX-880 in Type 1 diabetes (T1D). The high end of our fair value estimate range for Vertex stands at $640 per share.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please
login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.